Aberrant, uncontrolled activation of receptor tyrosine kinases (RTKs) is the "original sin" of many human cancers, in that this activation can both initiate and drive the evolution of tumors (1). Mutation and overexpression of the multiple members of the epidermal growth factor/ErbB receptor family, to cite only a single example, constitute cancer drivers that have been clinically targeted by a panoply of biologic and small-molecule inhibitors for more than a decade (2, 3) . Given the consequences of their activation, RTKs are always tightly regulated: their steady-state enzymatic (tyrosine kinase) activity is very low in the absence of activation, which is normally triggered by the binding of a protein ligand to the RTK extracellular domain (4) . This aspect has made the identification of RTK ligands an especially important goal, and studies over the last three decades have uncovered the ligands for nearly all of the 58 RTKs encoded in the human genome. Two closely related RTKsthe anaplastic lymphoma kinase (ALK) and the leukocyte tyrosine kinase (LTK)-have been notable holdouts, in that they have remained receptor "orphans" without a ligand. This is no longer the case. In PNAS, Reshetnyak et al. (5) identify "family with sequence similarity" (FAM) 150A and 150B-rechristened augmentor-β and augmentor-α, respectively, by the authors-as protein ligands for ALK and LTK.
These two RTKs share distinctive structural features, including highly conserved tyrosine kinase domains and unusual glycine-rich regions in their ligand-binding extracellular domains (ectodomains) that exhibit 55% amino acid identity between the receptors. ALK has been very widely studied in cancer (6) , particularly in nonsmall-cell lung carcinoma, neuroblastoma, and anaplastic largecell lymphoma, with which it was first associated (7). ALK-driven cancers have been seen to arise from gene fusion events between the ALK kinase domain and various protein-coding domains, by mutations in fulllength ALK, or via overexpression of the ALK protein. Crizotinib, ceritinib, and other smallmolecule ALK inhibitors are now used as therapies for nonsmall-cell lung carcinoma (8) . This clinical activity notwithstanding, the biological roles that ALK plays in either vertebrate development or mature physiology are not well understood. ALK knockout mice do not display strong phenotypes, although defects in mature brain (cortical and hippocampal) function have been reported (9) . LTK is murkier still: experiments in zebrafish Reshetnyak et al. identify "family with sequence similarity" (FAM) 150A and 150B-rechristened augmentor-β and augmentor-α, respectively, by the authors-as protein ligands for ALK and LTK.
are consistent with a role in neural crest cell development (10) , and genome-wide association studies have linked polymorphisms in the human LTK gene to lupus (11) , but its role in cancer remains unclear. Guan et al. (13) also coexpressed human ALK with either FAM150A or FAM150B in vivo, in the developing Drosophila eye. Expression of FAM150A, FAM150B, or human (wild-type) ALK alone yielded no perturbation of fly eye development, but expression of either FAM150A or FAM150B together with human ALK resulted in a rough eye phenotype (13) . Again, however, the expression levels of the ligands and the receptors were uncontrolled, and it is possible that these levels were anomalously high.
An additional unresolved issue with respect to ALK activation specifically relates to the role of heparin and heparan sulfate proteoglycans (HSPGs) in the modulation of ALK signaling. In studies published earlier this year, Murray et al., also in the Schlessinger group, identified heparin as an activating ligand for ALK in NB-1 neuroblastoma cells (14) . These investigators found that acidic sulfated glycosaminoglycan polymers bound to the very basic amino terminus of ALK, and strongly potentiated ALK autophosphorylation in NB-1 cells. This was of particular interest because HSPGs are well-known modulators of FGF binding and signaling through FGF receptors (15) . Heparin activation of ALK raised the possibility that HSPGs were interacting with an at-the-time unknown protein ligand (FAM150A or B?) for this receptor (16).
When Reshetnyak et al. (5) examined this issue, they found that heparin potentiated ALK signaling in NB-1 cells when coapplied together with a very low concentration (0.064 nM) of AUG-α, but that at higher concentrations this potentiation was overshadowed by the effect of AUG-α alone; and similar activation of ALK by heparin was seen neither in NIH 3T3 cells stably expressing ALK, nor by the Palmer group (13) (who found that heparin indeed binds to FAM150A) in IMR-32 cells. The exact position of HSPGs in the hierarchy of ALK signaling, therefore, awaits further functional, biochemical, and structural analyses.
Although there is still work to be done, the studies of Zhang et al. (12) , Guan et al. (13) , and Reshetnyak et al. (5) unambiguously position AUG-α/β (FAM150B/A) as protein ligands for the ALK/LTK family. These analyses reflect the closing of an era, in that we can soon look forward to the day when the RTK orphanage is finally shuttered.
